233 related articles for article (PubMed ID: 30695050)
1. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2019; 14(1):e0211268. PubMed ID: 30695050
[TBL] [Abstract][Full Text] [Related]
2. Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Sun Y; Jiang W; Lu W; Song M; Liu K; Chen P; Chang A; Ling J; Chiao PJ; Hu Y; Huang P
Int J Oncol; 2018 Sep; 53(3):1237-1246. PubMed ID: 29956742
[TBL] [Abstract][Full Text] [Related]
3. Repositioning approved drugs for the treatment of problematic cancers using a screening approach.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2017; 12(2):e0171052. PubMed ID: 28166232
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
[TBL] [Abstract][Full Text] [Related]
6. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
7. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
Zhang BY; Wang YM; Gong H; Zhao H; Lv XY; Yuan GH; Han SR
Int J Clin Exp Pathol; 2015; 8(1):25-37. PubMed ID: 25755690
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
Pujol JL; von Pawel J; Tumolo S; Martoni A; Hearn S; Fields SZ; Ross G
Oncology; 2001; 61 Suppl 1():47-54. PubMed ID: 11598415
[TBL] [Abstract][Full Text] [Related]
9. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
11. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.
Fiebiger W; Olszewski U; Ulsperger E; Geissler K; Hamilton G
Clin Transl Oncol; 2011 Jan; 13(1):43-9. PubMed ID: 21239354
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
14. A systematic overview of chemotherapy effects in non-small cell lung cancer.
Sörenson S; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
[TBL] [Abstract][Full Text] [Related]
15. Comparative oncology approach to drug repurposing in osteosarcoma.
Parrales A; McDonald P; Ottomeyer M; Roy A; Shoenen FJ; Broward M; Bruns T; Thamm DH; Weir SJ; Neville KA; Iwakuma T; Fulbright JM
PLoS One; 2018; 13(3):e0194224. PubMed ID: 29579058
[TBL] [Abstract][Full Text] [Related]
16. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
Perez RP; Perez KM; Handel LM; Hamilton TC
Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
[TBL] [Abstract][Full Text] [Related]
17. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
18. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
Novello S; Le Chevalier T
Semin Oncol; 2001 Aug; 28(4 Suppl 14):3-9. PubMed ID: 11605176
[TBL] [Abstract][Full Text] [Related]
19. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.
O'Neil J; Benita Y; Feldman I; Chenard M; Roberts B; Liu Y; Li J; Kral A; Lejnine S; Loboda A; Arthur W; Cristescu R; Haines BB; Winter C; Zhang T; Bloecher A; Shumway SD
Mol Cancer Ther; 2016 Jun; 15(6):1155-62. PubMed ID: 26983881
[TBL] [Abstract][Full Text] [Related]
20. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]